Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | HCN1 | O60741 | 6/20 | 0.59 |
| ▸ | HCN4 | Q9Y3Q4 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16510718 | 0.91 | TP53 (0.66) | TP53LMNATHRBMEN1KMT2A | |
| SCHEMBL16233178 | 0.90 | TP53 (0.60) | TP53LMNATHRBMEN1KMT2A | |
| SCHEMBL16233224 | 0.85 | HCN1 (0.61) | TP53LMNATHRBMEN1KMT2A | |
| SCHEMBL14835994 | 0.85 | SLC6A9 (0.78) | TP53 | |
| Hydrochloric Acid SCHEMBL16496619 | 0.85 | SLC6A9 (0.77) | TP53 | |
| SCHEMBL16233241 | 0.85 | TP53 (1.00) | TP53LMNATHRBMEN1KMT2A | |
| SCHEMBL16233232 | 0.84 | SLC6A5 (0.70) | TP53OPRM1SIGMAR1HCN1HCN4 | |
| SCHEMBL16233227 | 0.82 | MEN1 (0.57) | TP53LMNAMEN1KMT2AHCN1 | |
| SCHEMBL16233199 | 0.82 | LMNA (0.56) | TP53LMNATHRBMEN1KMT2A | |
| SCHEMBL16233240 | 0.80 | PARP10 (0.53) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | TP53 4562/4885LMNA 3607/4885THRB 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.